A carregar...
Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
PURPOSE: Axitinib, an orally administered vascular endothelial growth factor receptors 1, 2, and 3 inhibitor, is widely used as the second-line treatment for metastatic renal cell carcinoma. We present a case of metastatic renal cell carcinoma who developed a novel ocular adverse event, impaired ret...
Na minha lista:
| Publicado no: | Case Rep Ophthalmol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6489367/ https://ncbi.nlm.nih.gov/pubmed/31097940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000496197 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|